Your browser doesn't support javascript.
loading
Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group).
Erol, Cihan; Sakin, Abdullah; Basoglu, Tugba; Özden, Ercan; Çabuk, Devrim; Dogan, Mutlu; Öksüzoglu, Berna; Yildirim, Hasan Çagri; Öner, Irem; Eryilmaz, Melek Karakurt; Dülgar, Özgecan; Aydin, Dinçer; Dogan, Neslihan; Özen, Miraç; Hacibekiroglu, Ilhan; Özdemir, Nuriye; Gürler, Fatih; Paksoy, Nail; Karabulut, Senem; Aksoy, Asude; Hizal, Mutlu; Kahraman, Seda; Sen, Erdem; Paydas, Semra; Çilbir, Ebru; Firat, Feyza; Akdeniz, Nadiye; Özçelik, Melike; Oyman, Abdilkerim; Baytemür, Naziyet Köse; Acar, Ramazan; Almuradova, Elvina; Karabulut, Bülent; Sakalar, Teoman; Arak, Haci; Degerli, Ezgi; Türker, Sema; Alan, Özkan; Er, Özlem; Tasçi, Elif Senocak; Demir, Nazan; Çavdar, Eyyüp; Turhal, Serdar; Dede, Didem Sener; Akinci, Muhammed Bülent; Yalçin, Bülent; Yumuk, Fulden; Yalçin, Suayib; Sendur, Mehmet Ali Nahit.
  • Erol C; Department of Medical Oncology, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey.
  • Sakin A; Department of Medical Oncology, Faculty of Medicine, Van Yüzüncü Yil University, Van, Turkey.
  • Basoglu T; Department of Medical Oncology, School of Medicine, Marmara University, Istanbul, Turkey.
  • Özden E; Department of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey.
  • Çabuk D; Department of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey.
  • Dogan M; Department of Medical Oncology, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey.
  • Öksüzoglu B; Department of Medical Oncology, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey.
  • Yildirim HÇ; Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
  • Öner I; Department of Medical Oncology, Konya Meram State Hospital, Konya, Turkey.
  • Eryilmaz MK; Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.
  • Dülgar Ö; Department of Medical Oncology, Göztepe Training and Research Hospital, Istanbul Medeniyet University, Istanbul, Turkey.
  • Aydin D; Department of Medical Oncology, Derince Training and Research Hospital, Kocaeli, Turkey.
  • Dogan N; Department of Medical Oncology, Prof. Dr. A. Ilhan Özdemir Education and Research Hospital, Giresun University, Giresun, Turkey.
  • Özen M; Department of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya, Turkey.
  • Hacibekiroglu I; Department of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya, Turkey.
  • Özdemir N; Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.
  • Gürler F; Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.
  • Paksoy N; Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
  • Karabulut S; Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
  • Aksoy A; Department of Medical Oncology, Faculty of Medicine, Firat University, Elazig, Turkey.
  • Hizal M; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey.
  • Kahraman S; Department of Medical Oncology, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey.
  • Sen E; Department of Medical Oncology, Çanakkale Mehmet Akif Ersoy State Hospital, Çanakkale, Turkey.
  • Paydas S; Department of Medical Oncology, Faculty of Medicine, Çukurova University, Adana, Turkey.
  • Çilbir E; Department of Medical Oncology, Diskapi Training and Research Hospital, Ankara, Turkey.
  • Firat F; Department of Medical Oncology, Faculty of Medicine, Inönü University, Malatya, Turkey.
  • Akdeniz N; Department of Medical Oncology, Adiyaman Training and Research Hospital, Adiyaman, Turkey.
  • Özçelik M; Department of Medical Oncology, Ümraniye Education and Research Hospital, Istanbul, Turkey.
  • Oyman A; Department of Medical Oncology, Ümraniye Education and Research Hospital, Istanbul, Turkey.
  • Baytemür NK; Department of Medical Oncology, Memorial Ankara Hospital, Ankara, Turkey.
  • Acar R; Department of Medical Oncology, Gülhane Education and Research Hospital, Ankara, Turkey.
  • Almuradova E; Department of Medical Oncology, Faculty of Medicine, Ege University, Izmir, Turkey.
  • Karabulut B; Department of Medical Oncology, Faculty of Medicine, Ege University, Izmir, Turkey.
  • Sakalar T; Department of Medical Oncology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkey.
  • Arak H; Department of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.
  • Degerli E; Department of Medical Oncology, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey.
  • Türker S; Department of Medical Oncology, Zonguldak Atatürk State Hospital, Zonguldak, Turkey.
  • Alan Ö; Department of Medical Oncology, Tekirdag State Hospital, Tekirdag, Turkey.
  • Er Ö; Department of Medical Oncology, Acibadem Maslak Hospital, Istanbul, Turkey.
  • Tasçi ES; Department of Medical Oncology, Acibadem Maslak Hospital, Istanbul, Turkey.
  • Demir N; Department of Medical Oncology, Faculty of Medicine, Osmangazi University, Eskisehir, Turkey.
  • Çavdar E; Department of Medical Oncology, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey.
  • Turhal S; Department of Medical Oncology, Anadolu Medical Center, Kocaeli, Turkey.
  • Dede DS; Department of Medical Oncology, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turke.
  • Akinci MB; Department of Medical Oncology, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turke.
  • Yalçin B; Department of Medical Oncology, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turke.
  • Yumuk F; Department of Medical Oncology, School of Medicine, Marmara University, Istanbul, Turkey.
  • Yalçin S; Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
  • Sendur MAN; Department of Medical Oncology, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turke.
Turk J Med Sci ; 52(4): 1022-1032, 2022 Aug.
Article en En | MEDLINE | ID: mdl-36326360
BACKGROUND: Perioperative FLOT regimen is a standard of care in locally advanced operable gastric and GEJ adenocarcinoma. We aimed to determine the efficacy, prognostic factors of perioperative FLOT chemotherapy in real-life gastric and GEJ tumors. METHODS: The data of patients who were treated with perioperative FLOT chemotherapy were retrospectively analyzed from 34 different oncology centers in Turkey. Baseline clinical and demographic characteristics, pretreatment laboratory values, histological and molecular characteristics were recorded. RESULTS: A total of 441 patients were included in the study. The median of age our study population was 60 years. The majority of patients with radiological staging were cT3-4N(+) (89.9%, n = 338). After median 13.5 months (IQR: 8.5-20.5) follow-up, the median overall survival was NR (95% CI, NR to NR), and median disease free survival was 22.9 (95% CI, 18.6 to 27.3) months. The estimated overall survival at 24 months was 62%. Complete pathological response (pCR) and near pCR was achieved in 23.8% of all patients. Patients with lower NLR or PLR have significantly longer median OS (p = 0.007 and p = 0.033, respectively), and patients with lower NLR have significantly longer median DFS (p = 0.039), but PLR level did not affect DFS (p = 0.062). The OS and DFS of patients with better ECOG performance scores and those who could receive FLOT as adjuvant chemotherapy instead of other regimens were found to be better. NLR was found to be independent prognostic factor for OS in the multivariant analysis. At least one adverse event reported in 57.6% of the patients and grade 3-4 toxicity was seen in 23.6% patients. DISCUSSION: Real-life perioperative FLOT regimen in operable gastric and GEJ tumors showed similar oncologic outcomes compared to clinical trials. Better performance status, receiving adjuvant chemotherapy as same regimen, low grade and low NLR and PLR improved outcomes in real-life. However, in multivariate analysis, only NLR affected OS.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans / Middle aged País como asunto: Asia Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans / Middle aged País como asunto: Asia Idioma: En Año: 2022 Tipo del documento: Article